Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein

Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. We tested a recombinant modified vaccinia virus Ankara (MVA) vaccine expressing full-length MERS-CoV spike (S) glycoprotein by immunizing BALB/c mice with either intramuscular or subcutaneous regimen...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Virol
Päätekijät: Volz, Asisa, Kupke, Alexandra, Song, Fei, Jany, Sylvia, Fux, Robert, Shams-Eldin, Hosam, Schmidt, Jörg, Becker, Christin, Eickmann, Markus, Becker, Stephan, Sutter, Gerd
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2015
Aiheet:
Vaccines and Antiviral Agents
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4524222/
https://ncbi.nlm.nih.gov/pubmed/26018172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00614-15
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia